Haysaw, Hopefully Samyang will decide to convert, and Cortex can thus conserve the cash.
As I see it, from the current low stock price there should be big upside IF Cortex can get to the ADHD results (approx Q4-2011) and then ink an ADHD pharma deal. But reaching those goals will require raising more money.
Some potential nearer term catalysts for the stock include -
- IND acceptance by FDA (Psychiatric/Laughren), allowing the ADHD trial to start
- SA results - 'end of Summer' (figure Fall)
- ADHD trial starting in Q3
- Re-acquiring Schizo-Dep rights from Merck
- High Impacts related partnership
Market Data 
Markets 
AI
